Inhaled corticosteroids and the increased risk of pneumonia: What's new? A 2015 updated review

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 3, 2016, Pages 235-255

  Iannella, Hernan ^a   Luna, Carlos ^a   Waterer, Grant ^b  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

adverse effects; chronic obstructive pulmonary disease (COPD); inhaled corticosteroids; mortality; phenotypes; pneumonia

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; FORMOTEROL; VILANTEROL; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; GLUCOCORTICOID;

BACTERIAL LOAD; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; META ANALYSIS (TOPIC); MORTALITY RATE; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; DOSE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ANDROSTADIENES; BRONCHODILATOR AGENTS; BUDESONIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84973582900     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465816630208     Document Type: Review

References (111)

1. Agusti A., Fabbri L., (2014) Inhaled steroids in COPD: when should they be used? Lancet Respir Med 2: 869-871.
2. Alcázar Navarrete B., Casanova C., Miravitlles M., de Lucas P., Riesco J., Rodríguez González-Moro J., et al.(2015) Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease: a consensus document. Arch Bronconeumol 51: 193-198.
3. Almirall J., Bolibar I., Serra-Prat M., Roig J., Hospital I., Carandell E., et al.(2008) New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31: 1274-1284.
4. Andréjak C., Nielsen R., Thomsen V., Duhaut P., Sørensen H., Thomsen R, (2013) Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 68: 256-262.
5. Anzueto A., Ferguson G., Feldman G., Chinsky K., Seibert A., Emmett A., (2009) Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 6: 320-329.
6. Bafadhel M., McKenna S., Terry S., et al. (2012) Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 186: 48-55.
7. Blum C., Nigro N., Briel M., Schuetz P., Ullmer E., Suter-Widmer I., et al. (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385: 1511-1518.
8. Brightling C., McKenna S., Hargadon B., Birring S., Green R., Siva R., et al. (2005) Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 60: 193-198.
9. Calverley P., Anderson J., Celli B., Ferguson G., Jenkins C., Jones P., et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789.
10. Calverley P., Stockley R., Seemungal T., Hagan G., Willits L., Riley J., et al. (2011) Reported Pneumonia in COPD: Findings From the INSPIRE Study. Chest 139: 505-512.
11. Chen D., Restrepo M., Fine M., Pugh M., Anzueto A., Metersky M., et al. (2011) Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 184: 312-316.
12. Chong J., Leung B., Poole P., (2013) Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 11: CD002309.
13. Corrado A., Rossi A., (2012) How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 106: 989-997.
14. Crim C., Dransfield M., Bourbeau J., Jones P., Hanania N., Mahler D., et al. (2015) Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 12: 27-34.
15. Criner G., Bourbeau J., Diekemper R., Ouellette D., Goodridge D., Hernandez P., et al. (2015) Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 147: 894-942.
16. Crisafulli E., Menéndez R., Huerta A., Martinez R., Montull B., Clini E., et al. (2013) Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest 143: 1009-1017.
17. Crisafulli E., Guerrero M., Menéndez R., Huerta A., Martinez R., Gimeno A., et al. (2014) Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. Respir Care 59: 1550-1559.
18. Dickson R., Erb-Downward J., Huffnagle G., (2014) Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med 2: 238-246.
19. DiSantostefano R., Sampson T., Le H., Hinds D., Davis K., Bakerly N, (2014) Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One 9: e97149.
20. Dong Y., Chang H., Lin Wu F., Shen L., Calverley P., Löfdahl C., et al. (2014) Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza. Chest 145: 1286-1297.
21. Dransfield M., Bourbeau J., Jones P., Hanania N., Mahler D., Vestbo J., et al. (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 1: 210-223.
22. Drummond M., Dasenbrook E., Pitz M., Murphy D., Fan E,. (2008) Inhaled corticosteroids in patients with stable COPD: a systematic review and meta-analysis. JAMA 300: 2407-2416.
23. Electronic Medicines Compendium (eMC) (2015a) Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed. Updated 7 2015. www.medicines.org.uk/emc/medicine/28495 (. accessed 2 June 2015).
24. Electronic Medicines Compendium (eMC) (2015b) Seretide 100, 250, 500 Accuhaler. Updated 24 2015. www.medicines.org.uk/emc/medicine/2317 (. accessed 17 June 2015).
25. Ernst P., Gonzalez A., Brassard P., Suissa S., et al.(2007) Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176: 162-166.
26. Ernst P., Saad N., Suissa S., (2015) Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 45: 525-537.
27. Eurich D., Lee C., Marrie T., Majumdar S,. (2013) Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis 57: 1138-1144.
28. Fabbri L., Romagnoli M., Corbetta L., Casoni G., Busljetic K., Turato G., et al. (2003) Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167: 418-424.
29. Farr B., Bartlett C., Wadsworth J., Miller D,. (2000) Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 94: 954-963.
30. Ferguson G., Anzueto A., Fei R., Emmett A., Knobil K., Kalberg C,. (2008) Effect of fluticasone propionate/salmeterol (250/50 mg) or salmeterol (50 mg) on COPD exacerbations. Respir Med 102: 1099-1108.
31. Ferrer M., Torres A., Martínez R., Ramírez P., Polverino E., Montull B., et al. (2014) Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: A prospective clinical study. Respirology 19: 929-935.
32. Festic E., Bansal V., Gajic O., et al. (2014) Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc 89: 154-162.
33. Fine M., Auble T., Yealy D., Hanusa B., Weissfeld L., Singer D., et al. (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336: 243-250.
34. Garcha D., Thurston S., Patel A., Mackay A., Goldring J., Donaldson G., et al. (2012) Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 67: 1075-1080.
35. Gershon A., Campitelli M., Croxford R., Stanbrook M., To T., Upshur R., et al. (2014) Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 312: 1114-1121.
36. GOLD (2011) Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (updated January 2015). http://www.goldcopd.org (. accessed 26 February 2015).
37. Gutierrez P., Closa D., Piñer R., Bulbena O., Menéndez R., Torres A,. (2010) Macrophage activation in exacerbated chronic obstructive pulmonary disease with and without community acquired pneumonia. Eur Respir J 36: 285-291.
38. Halpin D., Gray J., Edwards S., Morais J., Singh D,. (2011) Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomized controlled trials. Int J Clin Pract 65: 764-774.
39. Han M., Agusti A., Calverley P., Celli B., Criner G., Curtis J., et al. (2010) Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 182: 598-604.
40. Hojo M., Iikura M., Hirano S., Sugiyama H., Kobayashi N., Kudo K,. (2012) Increased risk of nontuberculous mycobacterial infection in asthmatic patients using long-term inhaled corticosteroid therapy. Respirology 17: 185-190.
41. Huang Y., Sethi S., Murphy T., Nariya S., Boushey H., Lynch S,. (2014) Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol 52: 2813-2823.
42. Huerta A., Crisafulli E., Menéndez R., Martínez R., Soler N., Guerrero M., et al. (2013) Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest 144: 1134-1142.
43. Hurst J., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., et al. (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128-1138.
44. Janson C., Larsson K., Lisspers K., Ställberg B., Stratelis G., Goike H., (2013) Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 346: f3306.
45. Jen R., Rennard S., Sin D., (2012) Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 7: 587-595.
46. Johnson M., (1998) Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 101: S434-S439.
47. Joo M., Au D., Fitzgibbon M., Lee T., (2010) Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 104: 246-252.
48. Kardos P., Wencker M., Glaab T., Vogelmeier C,. (2007) Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 144-149.
49. Kern D., Davis J., Williams S., Tunceli O., Wu B., Hollis S., et al. (2015) Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res 23 2015. [Epub ahead of print]
50. Kew K., Seniukovich A., (2014) Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 10 (3): CD010115.
51. Kitaguchi Y., Komatsu Y., Fujimoto K., Hanaoka M., Kubo K,. (2012) Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 7: 283-289.
52. Larsson K., Janson C., Lisspers K., Jørgensen L., Stratelis G., Telg G., et al. (2013) Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med 273: 584-594.
53. Lipworth B., (1999) Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 159: 941-955.
54. Loke Y., Singh S., (2009) Inhaled corticosteroids in patients with COPD. JAMA 301: 1432-1434.
55. Loke, et al. (2011)
56. Loke Y., Kwok C., Wong J., et al. (2013) Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. Int J Clin Pract 67: 477-487.
57. Magnussen H., Disse B., Rodriguez-Roisin R., et al. (2014) Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371: 1285-1294.
58. Malo de Molina R., Mortensen E., Restrepo M., Copeland L., Pugh M., Anzueto A,. (2010) Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia. Eur Respir J 36: 751-757.
59. Mapel D., Schum M., Yood M., Brown J., Miller D., Davis K,. (2010) Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 19: 109-117.
60. Martinez R., Menendez R., Reyes S., Polverino E., Cillóniz C., Martínez A., (2011) Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J 37: 393-399.
61. Martinez F., Calverley P., Goehring U., Brose M., Fabbri L., Rabe K,. (2015) Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385: 857-866.
62. Miravitlles M., Soler-Cataluña J., Calle M., Soriano J., (2013) Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J 41: 1252-1256.
63. Miravitlles M., Anzueto A., (2015) Role of infection in exacerbations of chronic obstructive pulmonary disease. Curr Opin Pulm Med 21: 278-283.
64. Nannini L., Cates C., Lasserson T., Poole P,. (2007) Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4: CD006829.
65. Nannini L., Lasserson T., Poole P,. (2012) Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 9: CD006829.
66. Nie W., Zhang Y., Cheng J., Xiu Q., et al.(2012) Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One 7: e47926.
67. Ni S., Fu Z., Zhao J., Liu H., (2014) Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-analysis. J Thorac Dis 6: 971-978.
68. O'Byrne P., Pedersen S., Carlsson L., Radner F., Thorén A., Peterson S., et al. (2011) Risks of pneumonia in asthmatic patients taking inhaled corticosteroids. Am J Respir Crit Care Med 183: 589-595.
69. Pascoe S., Locantore N., Dransfield M., Barnes N., Pavord I., et al.(2015) Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3: 435-442.
70. Patel I., Seemungal T., Wilks M., Lloyd-Owen S., Donaldson G., Wedzicha J., (2002) Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57: 759-764.
71. Patel I., Vlahos I., Wilkinson T., Lloyd-Owen S., Donaldson G., Wilks M., et al. (2004) Bronchiectasis, exacerbations indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170: 400-407.
72. Pragman A., Kim H., Reilly C., et al. (2012) The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 7: e47305.
73. Rello J., Rodriguez A., Torres A., Roig J., Sole-Violan J., Garnacho-Montero J., et al. (2006) Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 27: 1210-1216.
74. Rennard S., Tashkin D., McElhattan J., Goldman M., Ramachandran S., Martin U., et al. (2009) Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 69: 549-565.
75. Restrepo M., Mortensen E., Pugh J., Anzueto A,. (2006) COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 28: 346-351.
76. Rodrigo G., Castro-Rodriguez J., Plaza V., (2009) Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs. long-acting betaagonists monotherapy for stable COPD: a systematic review. Chest 136: 1029-1038.
77. Rossi A., Guerriero M., Corrado A., (2014a) Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: A real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 15: 77.
78. Rossi A., van der Molen T., del Olmo R., Papi A., Wehbe L., Quinn M., et al. (2014) INSTEAD: a randomized switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J 44: 1548-1556.
79. Rossios C., To Y., To M., Ito M., Barnes P., Adcock I., et al. (2011) Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 670: 244-251.
80. Salluh J., Póvoa P., Soares M., Castro-Faria-Neto H., Bozza F., Bozza P,. (2008) The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit Care 12 (3): R76.
81. Sellares J., López-Giraldo A., Lucena C., Cilloniz C., Amaro R., Polverino E., et al. (2013) Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 187: 1241-1248.
82. Sethi S., Sethi R., Eschberger K., Lobbins P., Cai X., Grant B., et al. (2007) Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176: 356-361.
83. Sharafkhaneh A., Southard J., Goldman M., Uryniak T., Martin U,. (2012) Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 106: 257-268.
84. Siemieniuk R., Meade M., Alonso-Coello P., Briel M., Evaniew N., Prasad M., et al. (2015) Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163: 519-528.
85. Sin D., Tashkin D., Xuekui Zhang X., et al. (2009) Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 374: 712-719.
86. Singanayagam A., Chalmers J., Hill A,. (2010) Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 103: 379-385.
87. Singanayagam A., Chalmers J., Akram A., Hill A,. (2011) Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 38: 36-41.
88. Singh S., Amin A., Loke Y,. (2009) Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 169: 219-229.
89. Singh S., Loke Y., (2010) Risk of pneumonia associated with long-term use of inhaled corticosteroids in COPD: A critical review and update. Curr Opin Pulm Med 16: 118-122.
90. Singh D., Kolsum U., Brightling C., Locantore N., Agusti A., Tal-Singer R,. (2014) Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 44: 1697-1700.
91. Snijders D., Van Der Eerden M., De Graaff C., Boersma W,. (2010) The influence of COPD on mortality and severity scoring in community-acquired pneumonia. Respiration 79: 46-53.
92. Suissa S,. (2013a) Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 68: 540-543.
93. Suissa S., Patenaude V., Lapi F., Ernst P,. (2013b) Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68: 1029-1036.
94. Suissa S., Coulombe J., Ernst P,. (2015) Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest 148: 1177-1183.
95. Tagami T., Matsui H., Horiguchi H., Fushimi K., Yasunaga H,. (2015) Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J 45: 463-472.
96. Tashkin D., Rennard S., Martin P., Ramachandran S., Martin U., Silkoff P., et al. (2008) Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 68: 1975-2000.
97. Tashkin D., Doherty D., Kerwin E., Matiz-Bueno C., Knorr B., Shekar T., et al. (2012) Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 7: 73-86.
98. Thornton Snider J., Luna Y., Wong K., Zhang J., Chen S., Gless P., et al. (2012) Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin 28: 1959-1967.
99. Tomczyk S., Bennett N., Stoecker C., Gierke R., Moore M., Whitney C., et al. (2014) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged 3/465 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63: 822-825.
100. Torres A., Sibila O., Ferrer M., Polverino E., Menendez R., Mensa J., et al. (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313: 677-686.
101. Turner A., Tamasi L., Schleich F., Hoxha M., Horvath I., Louis R., et al. (2015) Clinically relevant subgroups in COPD and asthma. Eur Respir Rev 24: 283-298.
102. Watz H., Ferguson G., Gronke L., Vob F., Abrahams R., Buhl R,. (2015) Inhaled Corticosteroid Plus Long-Acting β2-Agonist Therapy is Overused in the Treatment of Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analyses of Two 1-Year Studies. ATS Conference, Denver. Thematic Poster Session D37: A5784.
103. Wedzicha J., Calverley P., Seemungal T., Hagan G., Ansari Z., Stockley R,. (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: 19-26.
104. Welsh E., Cates C., Poole P,. (2013) Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 5: CD007891.
105. White P., Thornton H., Pinnock H., Georgopoulou S., Booth H,. (2013) Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study. PLoS One 8: e75221.
106. World Health Organization (2012) Vaccines against influenza WHO position paper-November 2012. Wkly Epidemiol Rec 87: 461-476.
107. Wolfe F., Caplan L., Michaud K., (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease modifying anti-rheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54: 628-634.
108. Wouters E., Postma D., Fokkens B., Hop W., Prins J., Kuipers A., et al. (2005) Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 60: 480-487.
109. Yan J., Gu W., Pan L., (2014) Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: A meta-analysis. Pulm Pharmacol Ther 27: 83-89.
110. Yawn B., Li Y., Tian H., Zhang J., Arcona S., Kahler K,. (2013) Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 8: 295-304.
111. Zhong N., Wang C., Zhou X., Zhang N., Humphries M., Wang L., et al. (2015) LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 10: 1015-1026.